Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ray, K.P.
19997  Ergebnisse:
Personensuche X
?
1

Physica status solidi 

Volume 75, Number 2: February 16  Physica status solidi ; Volume 75, Number 2, A
Abdel-Salam, F ; Abreu, R. A ; Akhmetov, V. D... - Reprint 2021 . , [2022]
Link: https://doi.org/10.1515/..
 
?
2

High long-term persistence to evolocumab treatment regimens..:

Ray, K K ; Perrone-Filardi, P ; Ebenbichler, C...
European Heart Journal.  43 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
3

Evolocumab treatment is associated with early and sustained..:

Ray, K K ; Perrone-Filardi, P ; Ebenbichler, C...
European Heart Journal.  43 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
4

Residual risk of major adverse cardiovascular and limb even..:

Vallejo-Vaz, A.J. ; Dharmayat, K.I. ; Nzeakor, N....
Atherosclerosis.  355 (2022)  - p. 31 , 2022
Link: https://doi.org/10.1016/..
 
?
5

Final results from the pan-European observational heymans s..:

Ray, K.K. ; Bruckert, E. ; Perrone-Filardi, P....
Atherosclerosis.  355 (2022)  - p. 14 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Global perspective of paediatric Familial Hypercholesterola..:

Dharmayat, K.I. ; Vallejo-Vaz, A.J. ; Stevens, C.A....
Atherosclerosis.  355 (2022)  - p. 13 , 2022
Link: https://doi.org/10.1016/..
 
?
7

Identification, characteristics and management of adults wi..:

Vallejo-Vaz, A.J. ; Stevens, C.A. ; Dharmayat, K.I....
Atherosclerosis.  355 (2022)  - p. 15-16 , 2022
Link: https://doi.org/10.1016/..
 
?
8

Atherothrombotic residual risk in coronary and peripheral a..:

Vallejo-Vaz, A ; Dharmayat, K I ; Nzeakor, N...
European Heart Journal.  42 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
9

Reduction in the risk of MACE with apabetalone in patients ..:

Toth, P P ; Schwartz, G G ; Nicholls, S J...
European Heart Journal.  42 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
10

Evolocumab use in Europe: clinical guidelines vs. reimburse..:

Ray, K K ; Bruckert, E ; Filardi, P...
European Heart Journal.  42 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
11

A systematic review and meta-analysis of the efficacy of me..:

Brandts, J. ; Dharmayat, K.I. ; Vallejo-Vaz, A.J....
Atherosclerosis.  331 (2021)  - p. e256-e257 , 2021
Link: https://doi.org/10.1016/..
 
?
12

Inter-individual variability in LDL-C reductions with incli..:

Wright, R.S ; Raal, F.J ; Kallend, D...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
13

Do European patients with peripeheral arterial disease rece..:

Ray, K.K ; Feudjo Tepie, M ; Catapano, A.L...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
14

Apabetalone, a selective BET protein inhibitor, reduces isc..:

Ray, K.K ; Nicholls, S.J ; Buhr, K.A...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
15

Characteristics of adults with heterozygous familial hyperc..:

Vallejo-Vaz, A.J. ; Dharmayat, K. ; Stevens, C....
Atherosclerosis.  315 (2020)  - p. e13 , 2020
Link: https://doi.org/10.1016/..
 
1-15